Patients with moderate to severe psoriasis treated with risankizumab for 52 weeks had better psoriasis area severity index (PASI) scores than those reported in trials that lasted 16 weeks, according to findings from a research letter published in the Journal of The European Academy of Dermatology and Venereology.
Investigators conducted an extension of prior phase 3, 16-week studies on the safety and efficacy of IL-23 inhibitor risankizumab for moderate to severe psoriasis, extending it to 36 and 52 weeks of treatment. They collected efficacy, safety, and drug survival rate data as well as baseline demographic and clinical characteristics of enrolled patients. Patients received risankizumab monotherapy and were only allowed to use emollients. The study concluded until February 2021.
Of 57 patients included in the study, 66.7% were men, and 96.5% completed the 52-week therapy. At week 52, 96.4% of patients achieved PASI-75, 85.5% achieved PASI-90, and 60% achieved PASI-100.
Women achieved PASI-75, 90 and 100 more frequently than men. PASI-90 and PASI-100 were more frequent in patients with PASI less than 20 at baseline (64.3% and 89.3%, respectively) than patients with PASI 20 or more at baseline (55.6% and 81.5%, respectively). PASI-75 achievement was not influenced by baseline PASI.
Patients with a BMI of less than 25 had more frequent PASI-90 and PASI-100 scores, and patients with a BMI of 25 or greater had more frequent PASI-50 and PASI-75 scores. Biologic-experienced patients achieved PASI-100 at week 36 and 52 (71.8% and 69.2%, respectively) more often than biologic-naïve patients (50% and 37.5%, respectively).
“This outcome emphasizes the increasing effectiveness of risankizumab in the long-term” as well as its “excellent tolerability,” the study authors wrote.
Disclosure: Several study authors declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of authors’ disclosures.
Hansel K, Zangrilli A, Bianchi L, et al. A 52-week update of a multicentre real-life experience on effectiveness and safety of risankizumab in psoriasis. J Eur Acad Dermatol Venereol. Published online September 12, 2021. doi:10.1111/jdv.17656